Alternative strategies for gene therapy of hemophilia.
Hemophilia A and B are monogenic disorders that were felt to be ideal targets for initiation of gene therapy. Although the first hemophilia gene therapy trial has been over 10 years ago, few trials are currently actively recruiting. Although preclinical studies in animals were promising, levels achieved in humans did not achieve long-term expression at adequate levels to achieve cures. Transplantation as a source of cellular replacement therapy for both hemophilia A and B have been successful following liver transplantation in which the recipient produces normal levels of either factor VIII (FVIII) or factor IX (FIX). Most of these transplants have been conducted for the treatment of liver failure rather than for "curing" hemophilia. There are a variety of new strategies for delivering the missing clotting factor through ectopic expression of the deficient protein. One approach uses hematopoietic stem cells using either a nonspecific promoter or using a lineage-specific promoter. An alternative strategy includes enhanced expression in endothelial cells or blood-outgrowth endothelial cells. An additional approach includes the expression of FVIII or FIX intraarticularly to mitigate the intraarticular bleeding that causes much of the disability for hemophilia patients. Because activated factor VII (FVIIa) can be used to treat patients with inhibitory antibodies to replacement clotting factors, preclinical gene therapy has been performed using platelet- or liver-targeted FVIIa expression. All of these newer approaches are just beginning to be explored in large animal models. Whereas improved recombinant replacement products continue to be the hallmark of hemophilia therapy, the frequency of replacement therapy is beginning to be addressed through longer-acting replacement products. A safe cure of hemophilia is still the desired goal, but many barriers must still be overcome.
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.
Robert R
RR
Montgomery
Qizhen
Q
Shi
D000818:Animals; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D006467:Hemophilia A / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D051379:Mice
D001779:Blood Coagulation Factors
Drug News Perspect. 2009 May;22(4):185-96
19536363
Blood. 1987 Jun;69(6):1721-4
3107632
Haematologica. 2009 May;94(5):670-8
19336741
Transplantation. 1984 Oct;38(4):319-27
6437023
J Thromb Haemost. 2007 Feb;5(2):352-61
17269937
Blood. 2003 Apr 15;101(8):2963-72
12515715
Acta Haematol. 2009;121(2-3):102-5
19506355
Am J Physiol. 1971 May;220(5):1147-54
4930132
Surgery. 1974 May;75(5):725-33
4824431
Nat Genet. 2000 Mar;24(3):257-61
10700178
Blood. 2002 Jan 15;99(2):457-62
11781225
Br J Haematol. 2008 Mar;140(5):479-87
18275425
Transl Res. 2007 Jul;150(1):30-9
17585861
N Engl J Med. 2001 Jun 7;344(23):1735-42
11396439
Nat Med. 2006 Mar;12(3):342-7
16474400
Mol Genet Metab. 2003 May;79(1):25-33
12765843
Blood. 2008 Oct 1;112(7):2713-21
18495954
J Clin Invest. 1983 Jun;71(6):1836-41
6408124
Mol Ther. 2008 Aug;16(8):1359-65
18523449
J Clin Invest. 1998 Feb 1;101(3):613-24
9449695
Blood. 2008 Dec 1;112(12):4532-41
18716130
J Clin Invest. 2004 Apr;113(7):1025-31
15057309
Blood. 2009 May 21;113(21):5364-5
19470440
J Thromb Haemost. 2010 Feb;8(2):276-85
19943872
Clin Adv Hematol Oncol. 2006 Jan;4(1):34-5
16562367
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):808-13
19139414
J Biol Chem. 1999 Jul 9;274(28):19587-92
10391893
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2689-95
11116073
J Clin Invest. 2006 Jul;116(7):1974-82
16823491
Stem Cells. 2007 Oct;25(10):2660-9
17615271
Blood. 2010 Jun 10;115(23):4678-88
20335222
Blood. 2003 Sep 15;102(6):2038-45
12763932
Blood. 2003 Dec 1;102(12):4006-13
12881300
Blood. 2010 Jun 10;115(23):4902-9
20351306
Blood. 2010 Aug 26;116(8):1235-43
20445020
J Thromb Haemost. 2005 Oct;3(10):2259-63
16194203
Mol Cell Biol. 1989 Mar;9(3):1233-42
2498645
Haemophilia. 2010 May;16 Suppl 3:24-8
20586798